Cover Image
市場調查報告書

癌症骨轉移:開發平台分析

Bone Metastasis - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 251586
出版日期 內容資訊 英文 107 Pages
訂單完成後即時交付
價格
Back to Top
癌症骨轉移:開發平台分析 Bone Metastasis - Pipeline Review, H2 2016
出版日期: 2016年10月19日 內容資訊: 英文 107 Pages
簡介

所謂癌症骨轉移是指癌細胞由原生部位轉移到骨頭,有骨頭痛、骨折、大小便失禁、腳無力等症狀。乳癌、前列腺癌、肺癌、甲狀腺癌、腎臟癌等特定癌症等是致病原因,治療方法方面有化療、手術、放射治療等。

本報告涵括全球癌症骨轉移治療藥的開發平台資訊,提供您目前開發平台狀況和最新趨勢,藥物簡介,再加上主要企業及開發中的產品評估等資訊,為您概述為以下內容。

目錄

簡介

  • 分析範圍

癌症骨轉移概要

治療藥的開發

  • 癌症骨轉移開發中產品:概要
  • 癌症骨轉移開發中產品:比較分析

癌症骨轉移:開發中的治療藥:各企業

癌症骨轉移:開發中的治療藥:各大學·研究機關

癌症骨轉移:開發中產品概況

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品

癌症骨轉移:開發中的產品:各企業

癌症骨轉移:開發中的產品:各大學·研究機關

癌症骨轉移:治療藥的開發企業

  • Ablynx NV
  • Aegera Therapeutics Inc.
  • Alethia Biotherapeutics Inc.
  • Amgen Inc.
  • Amura Holdings Limited
  • Bayer AG
  • ChemoCentryx, Inc.
  • Debiopharm International S.A.
  • Deciphera Pharmaceuticals, LLC
  • Digna Biotech, S.L.
  • Kyowa Hakko Kirin
  • Medivir AB
  • Merrion Pharmaceuticals Plc
  • Oncobiologics, Inc.
  • Oncodrone BV
  • Osteologix Holdings Plc
  • R-Pharm
  • Sigma-Tau S.p.A.
  • Terpenoid Therapeutics, Inc.
  • Thar Pharmaceuticals, Inc.

癌症骨轉移:治療藥的評估

  • 單劑治療藥
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • AB-25E9
  • ADM-01
  • ALX-0141
  • AM-3701
  • AMG-161
  • BMD-3151
  • CCX-721
  • DCC-3014
  • Debio-0719
  • Denosumab
  • Denosumab的生技仿製藥
  • disitertide
  • 癌症骨轉移用EGFR抑制劑
  • Ki-26894
  • MIV-711
  • NBS-101
  • OCD-155
  • P-17
  • radium Ra 223 dichloride
  • 癌症骨轉移·非小細胞肺癌基因改造型蛋白質
  • roneparstat
  • RPH-203
  • RSF-102
  • RSF-103
  • 免疫學·腫瘤學 cFMS 激酶阻礙小分子
  • 癌症·癌症骨轉移GGDPS阻礙小分子
  • TPH-9
  • Vicrostatin
  • 唑來膦酸
    • 產品概要
    • 作用機制
    • R&D的進展

最新的開發平台趨勢

暫停中的計劃

開發中止的產品

產品開發里程碑

  • 關注的新聞·新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8543IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Bone Metastasis - Pipeline Review, H2 2016, provides an overview of the Bone Metastasis (Oncology) pipeline landscape.

Bone metastasis occurs when cancer cells spread from their original site to a bone. Signs and symptoms of bone metastasis include bone pain, broken bones, urinary incontinence, bowel incontinence and weakness in the legs. The predisposing factors include certain kinds of cancer (breast, prostate, lung, thyroid, and kidney cancers). Treatment options for bone metastasis are chemotherapy, surgery and radiation therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Bone Metastasis - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Bone Metastasis (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Bone Metastasis (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Bone Metastasis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Preclinical and Discovery stages are 1, 1, 2, 17 and 1 respectively for Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 5 and 1 molecules, respectively for Bone Metastasis.

Bone Metastasis (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Bone Metastasis (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Bone Metastasis (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Bone Metastasis (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Bone Metastasis (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Bone Metastasis (Oncology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Bone Metastasis (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Bone Metastasis (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Bone Metastasis Overview
  • Therapeutics Development
    • Pipeline Products for Bone Metastasis - Overview
    • Pipeline Products for Bone Metastasis - Comparative Analysis
  • Bone Metastasis - Therapeutics under Development by Companies
  • Bone Metastasis - Therapeutics under Investigation by Universities/Institutes
  • Bone Metastasis - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Bone Metastasis - Products under Development by Companies
  • Bone Metastasis - Products under Investigation by Universities/Institutes
  • Bone Metastasis - Companies Involved in Therapeutics Development
    • Ablynx NV
    • Alethia Biotherapeutics Inc.
    • Amgen Inc.
    • Amura Holdings Limited
    • Bayer AG
    • BiologicsMD, Inc.
    • ChemoCentryx, Inc.
    • Deciphera Pharmaceuticals, LLC
    • Oncobiologics, Inc.
    • Oncodrone BV
    • Osteologix Holdings Plc.
    • R-Pharm
    • Taiho Pharmaceutical Co., Ltd.
    • Terpenoid Therapeutics Inc
  • Bone Metastasis - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • AB-25E9 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ADM-01 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ALX-0141 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AM-3701 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AMG-161 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BKM-1644 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BKM-1740 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BMD-3151 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CCX-354 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DCC-3014 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • denosumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • denosumab biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Drugs to Inhibit CXCL5 for Bone Metastasis and Breast Cancer - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LG-1980 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibodies to Inhibit SVEP1 for Bone Metastasis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NBS-101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • OCD-155 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • radium Ra 223 dichloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Protein for Bone Metastasis and Non-Small Cell Lung Cancer - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • roneparstat - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RPH-203 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RSF-102 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RSF-103 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit cFMS Kinase for Immunology and Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit GGDPS for Bone Metastasis and Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TAS-115 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TPH-9 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • vicrostatin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Bone Metastasis - Dormant Projects
  • Bone Metastasis - Discontinued Products
  • Bone Metastasis - Product Development Milestones
    • Featured News & Press Releases
      • May 18, 2016: Bayer to Showcase Latest Data on Xofigo (radium Ra 223 dichloride) at ASCO 2016
      • Mar 29, 2016: Bayer Receives Approval for Xofigo in Japan
      • Feb 03, 2016: NICE issues full guidance for Xofigoq (radium-223 dichloride)
      • Sep 14, 2015: Bayer to Present Data On Radium-223 Dichloride at ECC2015 in Vienna
      • Jul 06, 2015: R-Pharm Group of Companies Develops Original drug for Treatment of Metastatic Bone Disease
      • Oct 09, 2013: Medivir: Positive results from a phase I study with MIV-711 for the treatment of osteoarthritis and other bone related disorders
      • Oct 01, 2013: Goodwin Biotechnology Announces the Return of AB-25E9 Monoclonal Antibody Project from Alethia Biotherapeutics
      • Jul 17, 2013: The New England Journal of Medicine publishes results from the phase III ALSYMPCA study of Xofigo
      • Jun 20, 2013: Algeta Opens Commercial Production Facility For Xofigo Injection In Kjeller, Norway
      • May 30, 2013: Algeta Announces First Sale Of Xofigo In US
      • Feb 15, 2013: Algeta Presents Further Sub-analysis Of Phase III ALSYMPCA Study Of Radium-223 Dichloride At 2013 Genitourinary Cancers Symposium
      • Jan 14, 2013: US Nuclear Regulatory Commission Issues Licensing Decision For Radium-223 Dichloride
      • Sep 17, 2012: Bayer To Present Data On Alpharadin At ESMO 2012 Congress
      • Aug 21, 2012: Medivir Commences Phase Ib Trial Of MIV-711 For Treatment Of Skeletal Disorders
      • Jun 04, 2012: Bayer Reports Updated Data From Phase III Study Of Alpharadin For Treatment Of Prostate Cancer
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Bone Metastasis, H2 2016
  • Number of Products under Development for Bone Metastasis - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Bone Metastasis - Pipeline by Ablynx NV, H2 2016
  • Bone Metastasis - Pipeline by Alethia Biotherapeutics Inc., H2 2016
  • Bone Metastasis - Pipeline by Amgen Inc., H2 2016
  • Bone Metastasis - Pipeline by Amura Holdings Limited, H2 2016
  • Bone Metastasis - Pipeline by Bayer AG, H2 2016
  • Bone Metastasis - Pipeline by BiologicsMD, Inc., H2 2016
  • Bone Metastasis - Pipeline by ChemoCentryx, Inc., H2 2016
  • Bone Metastasis - Pipeline by Deciphera Pharmaceuticals, LLC, H2 2016
  • Bone Metastasis - Pipeline by Oncobiologics, Inc., H2 2016
  • Bone Metastasis - Pipeline by Oncodrone BV , H2 2016
  • Bone Metastasis - Pipeline by Osteologix Holdings Plc., H2 2016
  • Bone Metastasis - Pipeline by R-Pharm, H2 2016
  • Bone Metastasis - Pipeline by Taiho Pharmaceutical Co., Ltd., H2 2016
  • Bone Metastasis - Pipeline by Terpenoid Therapeutics Inc, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Bone Metastasis - Dormant Projects, H2 2016
  • Bone Metastasis - Dormant Projects (Contd..1), H2 2016
  • Bone Metastasis - Dormant Projects (Contd..2), H2 2016
  • Bone Metastasis - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Bone Metastasis, H2 2016
  • Number of Products under Development for Bone Metastasis - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top